| GTO ID | GTC2725 |
| Trial ID | NCT04945772 |
| Disease | Dystrophies Primarily Involving the Retinal Pigment Epithelium | Retinal Degeneration | Retinal Disease | Retinitis | Retinitis Pigmentosa |
| Altered gene | MCO |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | MCO-010 |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] |
| Year | 2021 |
| Country | Puerto Rico|United States |
| Company sponsor | Nanoscope Therapeutics Inc. |
| Other ID(s) | NTXMCO-002. |
| Vector information | |||||||||
|
|||||||||
| Cohort1: dose level 1 | |||||||||
|
|||||||||
| Cohort2: dose level 2 | |||||||||
|
|||||||||